LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs.

Trial Details

NCT ID
NCT06576635
Phase
NA
Sponsor
University of Illinois at Chicago
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Docetaxel
  • Paclitaxel
  • Gemcitabine
  • Pemetrexed
  • Vinorelbine
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Age ≥ 18 years of age at time of consent
  • ECOG performance status score of ≤2
  • Advanced non-small cell lung cancer to meet histologically confirmed Stage IV NSCLC documented by biopsy.
  • Patients have received at least 1 prior line of systemic therapy for Stage IV NSCLC, including but not limited to targeted therapy, and are current…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →